MAP2K7 and leukemia: Interestingly in the same study, the leukemia burden in both wtRAS(JAK2-mutant) and mutant-RAS xenograft models was reduced via MEK-inhibitor, representing a strongly corroborating evidence to some of the conclusions of our study.